Replies to post #12124 on GTC Biotherapeutics (fka GTCB)

[stockdak]

Cash guidance for 08' from ASM

Hi Dew,
I was looking at slide 24 of the ASM presentation and want to make sure I understand their cash position. $11.7 left at the end of 1Q. Breakeven for 2Q. $5 million in milestones from Ovation assuming FDA acceptance of the Atryn BLA. $10-12 cash burn for 2H 08'.

So they have $16.7 and will burn $10-12. So most likely they have cash through 4Q 08' with $4.7-$6.7 remaining at end of 4Q 08'.

From the LEO deal:
$38M for clinical/regulatory milestones in the DIC/sepsis indication
$30M for sales-based milestones

Are any of these milestones public? i.e how much for PII completion/PIII initiation and what sales levels trigger milestones?

T.I.A

[DewDiligence]

GTC’s Cash Usage for Remainder of 2008
(To be read in conjunction with #msg-30250952.)

[alertmeipp]

>GTC’s existing cash balance of $11.7M

Should be abit over 12M now...with latest deal.